Neuropathic Pain Management in Chronic Laminitis

This is the author's manuscript

Original Citation:

Availability:
This version is available http://hdl.handle.net/2318/77529 since

Terms of use:
Open Access
Anyone can freely access the full text of works made available as "Open Access". Works made available under a Creative Commons license can be used according to the terms and conditions of said license. Use of all other works requires consent of the right holder (author or publisher) if not exempted from copyright protection by the applicable law.

(Article begins on next page)
This is an author version of the contribution published on:

Questa è la versione dell’autore dell’opera:

Veterinary Clinics of North America: Equine Practice

Volume 26, August 2010,


Bernd Driessen, Sébastien H. Bauquier, Laura Zarucco,

26, Issue 2, Christopher C. Pollitt, 2010, pages 315-337

The definitive version is available at:

La versione definitiva è disponibile alla URL:

http://www.vetequine.theclinics.com
Pain (Neuropathic) Management of Chronic Laminitis

Bernd Driessen, DVM, PhD, Sébastien H. Bauquier, DMV and Laura Zarucco, DMV, PhD

a Section of Emergency/Critical Care and Anesthesia, Department of Clinical Studies-New Bolton Center, School of Veterinary Medicine, University of Pennsylvania, Kennett Square, Pennsylvania

b Department of Anesthesiology, David-Geffen School of Medicine, University of California-Los Angeles, Los Angeles, California

c Section of Critical Care, Department of Clinical Studies-Philadelphia, School of Veterinary Medicine, University of Pennsylvania, Philadelphia, Pennsylvania

d Dipartimento di Patologia Animale, Facoltà di Medicina Veterinaria, Università degli Studi di Torino, Grugliasco, Italy

KEYWORDS: • Horse • Laminitis • Neuropathic Pain • NSAIDs • Analgesics • Gabapentin

Corresponding author:
Bernd Driessen, DVM, PhD, Dipl. ACVA, Dipl. ECVPT, Section of Emergency/Critical Care and Anesthesia, Department of Clinical Studies-New Bolton Center, School of Veterinary Medicine, University of Pennsylvania, 382 West Street Road, Kennett Square, PA 19348, USA.
Office: +1 (610) 925-6130 Fax: +1 (610) 925-8120 e-mail: Driessen@vet.upenn.edu

Co-authors’ addresses:
Sébastien H. Bauquier, DVM, Section of Critical Care, Department of Clinical Studies-Philadelphia, School of Veterinary Medicine, University of Pennsylvania, 3850 Spruce Street, Philadelphia, PA 19104, USA.
Office: + 1 (267) 639 0940 e-mail: Bauquier@vet.upenn.edu

Laura Zarucco, DMV, PhD, Dipartimento di Patologia Animale, Facoltà di Medicina Veterinaria, Università degli Studi di Torino, Via Leonardo da Vinci 44, 10095 Grugliasco (TO), Italy.
Office: + 39 (349) 593-0110 e-mail: laura.zarucco@unito.it
Managing pain in horses afflicted by chronic laminitis is one of the greatest challenges in equine clinical practice because it is the dreadful suffering of the animals that most often forces the veterinarian to end the battle with this disease. The purpose of this review is to summarize our current understanding of the very complex mechanisms involved in generating and amplifying pain in animals with laminitis and based on this information to propose a modified approach to pain therapy. Furthermore a recently developed pain scoring technique is being presented that may help better quantify pain and the monitoring of responses to analgesic treatment in horses with laminitis.

MECHANISMS OF PAIN IN LAMINITIS

Understanding the neuroanatomy of the equine foot and pathophysiological processes involved in triggering and modifying nociception during the course of laminitis, though incompletely understood, is essential when searching for effective pain management strategies in affected animals. This applies even more if one considers that up to 75% of horses affected by this disease eventually develop severe or chronic lameness and debilitation. As emphasized by Orsini and colleagues inflammation emerges as the common pathological denominator in all cases of laminitis and thus also disease-related pain. It is intimately associated with the cascade of events that may eventually lead to the complete failure of the lamellar dermal-epidermal bond. Inflammation and vascular dysfunction are evident in the early developmental phase of laminitis, when pain or other clinical symptoms are still absent. During this prodromal phase leucocyte extravasation and development of platelet microthrombi are accompanied by up-regulated gene expression for key inflammatory cytokines (e.g. interleukin [IL]-1β, IL-6), cyclooxygenase (COX)-2, and matrix metalloproteinases (MMPs) in the digital laminae. Locally released and activated MMPs mediate degradation of the collagen components of the basement membrane (BM) that is interposed between the secondary dermal (SDL) and epidermal lamellae (SEL) and cause a separation of the SEL from the BM.

Sensory innervation of the foot consists of thick myelinated A-fibers (largely Aβ) transmitting low-threshold mechanical information and small thin myelinated (Aδ-fibers) and un-myelinated afferents (C-fibers) which express a variety of peptides and transmit high-threshold nociceptive information. The Aβ fibers innervate lamellated corpuscles (comparable with Pacinian corpuscles) clustered below the digital cushion in the heel segment of the hoof that function as proprioceptors and provide a secure gait. Both nociceptive Aδ- and C-fibers that stain
immunohistochemically positive for calcitonin gene-related peptide (CGRP) and substance P (SP) and are widely distributed throughout the base of the dermal layer (especially dermal papillae in the solear and bulbar segment and dermal lamellae in the parietal segment) and run parallel to blood vessels without innervating them. In addition, slow-conducting un-myelinated nerve fibers of the autonomic (exclusively sympathetic) nervous system accompany the dense network of blood vessels and arteriovenous anastomoses within the hoof capsule. As in visceral organs, these sympathetic nerves not only carry efferent fibers that regulate vasomotor tone, sweat glands and pilo erector muscles in the skin but also afferent viscerosensory fibers that signal information about vascular lumen, wall stress, and noxious stimulation or hypoxic/ischemic tissue conditions to the central nervous system (CNS). Hence, they may contribute to sympathetically maintained nociceptive stimulation typically unresponsive to conventional analgesics.

The inflammatory and disadhesion processes that occur during the developmental phase of laminitis do not seem to influence activity in sensory nerve fibers of the hoof. Histological data suggest that the disruption of the dermo-epidermal laminar bond is initially confined to the non-innervated basement membrane and epidermal lamellae (grade 1 histological laminitis). Since sensory nerve terminals are located primarily at the base of the dermal lamellae, at this stage of the disease they are likely too distant to the site of MMP action to be affected and SEL cell injury and local inflammation are not severe enough to cause activation through neurochemical signaling. Lacking pain or discomfort the developmental phase of laminitis often goes unnoticed and therefore treatment is not initiated even though aggressive medication with non-steroidal antiinflammatory drugs (NSAIDs) has been claimed to be indicated.

Unless resolving on their own histological changes at the dermal-epidermal interface progress further causing within 24-72 hours the BM to retract so much from SEL that SDL connective tissue and SDL capillaries are injured by tension and shear forces (grade 2 histological laminitis), likely provoking activation of perivascular sensory nerve terminals near the base of the dermal lamellae. At this point the developmental phase transits into the acute phase of laminitis that is hallmarked by classical signs of inflammation such as bounding digital pulses and increased hoof temperature. Nociception is most often recognized by lameness or the characteristic stance of the animal and rapidly increasing sensitivity to hoof testers. Even though evidence for a marked increase in COX-2 enzyme activity could not be found in the acute phase of experimentally induced laminitis, concentrations of other vasoactive degradation products of arachidonic acid (e.g. isoprostanes) are elevated during the acute phase of experimentally induced laminitis. In addition, extensive necrosis
of the SEL and edema with separation of the dermal-epidermal junction has been noted in the acute phase of experimentally induced laminitis.\textsuperscript{21} Thus, it is most likely that sensitization (\textit{peripheral hyperalgesia}) develops secondary to the action of a variety of locally released inflammatory products.\textsuperscript{15,16,22} As described in other situations of tissue damage, changes in the local environment (e.g. tissue pH and local electrolyte (K\textsuperscript{+}) concentrations, accumulation of membrane degradation products, cytokines, chemokines, and growth factors from invading inflammatory cells) and up-regulated enzyme systems may collectively activate both expressed and silent nociceptors and sensititize them to noxious and even non-noxious stimuli.\textsuperscript{22} Furthermore, activated sensory nerve fibers in the dermal papillary layer release neuropeptides (e.g. CGRP) which target receptors on blood vessels and provoke neurogenic inflammation by causing vasodilation, plasma extravasation, and leucocyte attraction.\textsuperscript{18,19} Even during the acute phase of laminitis, persistent afferent nociceptive signaling will initiate neural processes (addressed in detail below) that eventually create a state of central potentiation of nociceptive input to the brain (\textit{central hyperalgesia})\textsuperscript{22} mediated in part by spinal release of excitatory amino acids, tachykinins, prostanoids and cytokines.\textsuperscript{16} Some of these products reflect the activation of not only neurons, but also non-neuronal cells (astrocytes and microglia) which contribute to the release of products (e.g. prostaglandins) that in turn increase excitability of dorsal horn neurons.\textsuperscript{16,22} Both peripheral and early central hyperalgesia may explain the rapidly worsening pain horses and ponies experience in the acute phase of laminitis.

Animals may pass through the acute phase of mild and moderate laminitis without having developed any gross structural changes to the dermal-epidermal lamellar apparatus, allowing for complete recovery from all symptoms including pain. If not, they enter within 2-3 days the chronic phase of laminitis that begins with separation of the distal phalanx from the hoof wall and subsequent mechanical collapse of the foot.\textsuperscript{3-5} It can be subdivided into three subphases, i.e. early chronic, chronic stable, and active chronic laminitis.\textsuperscript{23} It is during the early chronic or active chronic phase of the disease process that relenting pain may develop which often is very difficult to control with traditional antiinflammatory and analgesic drug treatment.\textsuperscript{24} However, some animals may pass the early chronic phase rather rapidly without showing severe symptoms and enter the stage of chronic stable laminitis. At this stage they may not display any significant lameness allowing even athletic performance despite unequivocal radiographic evidence of displacement of the distal phalanx.\textsuperscript{21}

The pain animals with chronic laminitis suffer is multifactorial and greatly variable. The pathophysiological sequela occurring after structural failure of the lamellar suspensory apparatus in
one animal may or may not occur to the same extent in another and the type and scope of tissue repair and remodeling varies among individual horses. A major component determining the degree of nociception is the extent of mechanical/structural failure of the foot’s submural tissues, with global distal displacement of the digital phalanx (‘sinking’) probably representing the worst scenario. Tearing of the dermal-epidermal lamellar bond with rotation or sinking of the coffin bone results in widespread injury to C- and Aδ-fibers in the dermal layers. Damaged sensory neurons produce spontaneous impulse discharges that lead to sustained levels of excitability. These ectopic discharges begin to “cross talk” with adjacent uninjured nerve fibers, resulting in amplification of the response to noxious stimulation as part of the peripheral hyperalgesia that develops in the injured tissue. Distal phalanx displacement also leads to increased submural pressure from the edema that accompanies inflammation and/or hemorrhage. Loss of digital stability with significant shifts in the distribution of strain and stress forces within the hoof capsule contribute to both mechano- (Aβ) and nociceptor (Aδ, C) activities, as does elevated pressure on the coffin bone due to greater and longer lasting contact between the internal surface of the sole and the distal phalanx during locomotion. Elevated eicosanoid (PGE₂, LTB₄) concentrations have not been detected in digital venous blood of painful horses during chronic laminitis. Nevertheless, it appears that inflammatory mediators released throughout all phases of laminitis play a dominant role in the pain perception during early and active chronic laminitis. Furthermore, digital ischemia resulting from tearing of SDL arterioles, vasoconstriction (primarily venoconstriction) in response to inflammatory mediators, arteriovenous blood shunting, thrombosis, and compression of the solar vascular bed after digital collapse may contribute important causative factors for pain. Also dilation of hoof vessels in response to release of neuropeptides (e.g. CGRP) from activated sensory nerve terminals leads to a rapid increase in pressure within the hoof capsule (similar to the situation within the skull after vasodilation), thereby exacerbating foot pain.

The factors mentioned above only partially explain why many animals with chronic laminitis experience persistent and often times worsening pain that is refractory to therapy, while other animals are spared or recover. While not studied in detail in horses with laminitis, data obtained with laboratory animal models and clinical observations in human patients with severe tissue injury indicate that lesions to peripheral somatosensory neurons can trigger a complex series of events that eventually alter peripheral nerve impulse signaling and central nervous sensory input processing. These processes result in a pain state commonly referred to as neuropathic pain, i.e. pain that has its origin in a lesion or dysfunction of the sensory transmission pathways in the peripheral or central
The changes may include but are not limited to: i) large increases in spontaneous (ectopic) activity in injured afferent nerve fibers and dorsal root ganglia (DRG) cell bodies; ii) ectopic activity in nociceptors resulting from local increase in sodium channel expression and enhanced sensitivity to excitatory products released from local inflammatory cells; iii) facilitation of synaptic neurotransmission in the dorsal horn through increased release of or response to excitatory neurotransmitters (e.g. NMDA, glutamate) and/or increased ion channel conductance; iv) loss of dorsal horn inhibition otherwise mediated by spinal GABA- or glycergic interneurons; v) reduced sensitivity of primary sensory afferents and dorsal horn neurons towards the effects of µ-opioid agonists; vi) sprouting of central sympathetic nerve fiber terminals into layers of the dorsal horn where they can make abnormal contacts with ascending sensory neurons causing “sympathetically maintained pain”; vii) loss of synaptic connectivity and formation of new synaptic contacts between low-threshold Aβ fibers and ascending sensory neurons that normally receive input only from nociceptive Aδ and C fibers, causing allodynia (table 2); viii) activation of astrocytes and microglia leading to an increased spinal expression of pro-excitatory products including prostanoids; and ix) neuroimmune interactions including actions of MMPs 9 and 2 capable of inducing neuropathic pain through microglial and astrocyte activation. Ectopic neural firing activity occurs within 12 to 48 hrs after nerve injury, while sensitization and gene expression changes in spinal and maybe supraspinal neural networks begin later. Neural lesions alone may not be sufficient to generate neuropathic pain and other predisposing factors are of importance. Nevertheless, Jones and collaborators found in horses suffering from recurrent and treatment refractory laminitis, neuromorphological changes and altered gene expression that are strikingly similar to those changes observed in animal models of peripheral nerve injury or in humans with neuropathic pain (e.g., from arthritis, osteosarcoma, or diabetes). The nerve fiber composition of digital nerves harvested from affected animals was abnormal with significantly lower numbers of un-myelinated (43.2%) and myelinated fibers (34.6%) compared to nerves collected from normal horses. Furthermore, upregulated expression of activating transcription factor-3 (ATF3), a classical marker of peripheral nerve injury, was found in DRG cells of both large and small afferents. Also neuropeptide Y (NPY) expression was increased in DRG cells of large myelinated fibers innervating the laminitic hoof. The abundant presence of MMPs 2 and 9 from the developmental phase onwards may yet be another factor contributing to the development of neuropathic neural injury. Thus, it appears that mechanisms of peripheral and central sensitization and neuropathic remodeling described above can
play a central role in the development of the unrelenting pain experienced by so many horses during chronic laminitis. In this pain state mildly noxious or subthreshold stimuli (transmitted by small Aδ- and C-afferents) produce an exaggerated pain response due to amplified pre- and postsynaptic neuronal sensitivity and activity. Normally innocuous mechanical stimuli such as those activating the lamellated corpuscles and low threshold Aβ fibers in the heel area when the foot touches the ground during locomotion may then be perceived as painful (tactile or mechanical alldynia). This may explain the frequent limb shifting and high sensitivity to the hoof tester.

**GRADING PAIN IN LAMINITIS**

Various scoring systems employing either behavioral characteristics only or both behavioral and physiological parameters have been developed to monitor pain in horses. Obel was among the first to describe a grading system for lameness in horses affected by laminitis. Both the Obel Grading System and the later developed graded lameness scale (0-5) of the American Association of Equine Practitioners are subject to high inter-observer variability, do not fully account for the complexity of equine pain behaviors, and are somewhat limited when assessing clinically relevant changes in nociception and responses to therapy. Dutton and colleagues recently applied a modified composite multifactorial pain scoring system that includes components of the Obel Grading System and the Glasgow composite pain scale in a horse suffering from severe persistent foot pain (Table 1). As the authors emphasize multiple observers produced consistently similar scores when assessing the pain state in the horse and changes in scores tightly followed responses to analgesic treatment and progress in the disease process. To objectively assess and quantify pain (lameness) in acute and chronic laminitis, force plate systems have been used for measuring ground reaction forces and other force parameters and to identify changes in limb-load distribution pattern that reflect changes in the disease process and responses to treatment.

**PAIN THERAPY IN LAMINITIS: MODIFYING THE APPROACH**

Until very recently pain therapy in acute and chronic laminitis has largely been based on the proposed etiopathogenetic mechanisms underlying the disease (i.e. vascular or thromboembolic ischemia; inflammatory; metabolic; enzymatic and biomechanical mechanisms) and consisted predominantly of anti-inflammatory drug administration. In the acute phase this therapy was often combined with other medications (e.g., acepromazine, pentoxifylline, isoxuprine, heparin, acetyl salicylic acid, nitroglycerin,
dimethyl sulfoxide) addressing suspected ischemia and reperfusion injury (oxidative damage) in the dermal-epidermal lamellae, yet with conflicting results.39-43,45,46-48 This traditional approach failed to control the multifactorial pain in horses with chronic laminitis, because pain has been considered only a symptom of laminitis rather than a pathological entity in itself. It is the abnormal neural signal processing due to damage to tissues (inflammatory pain) and nervous structures (neuropathic pain), and/or abnormal function of the nervous system as a whole (functional pain) that over the course of the disease process causes a state of nociception that is commonly referred to as pathological or maladaptive pain.30,49 Conventional non-steroidal anti-inflammatory (NSAID) and other medications may not or only partially target the neuropathophysiological mechanisms described in detail above.15,16,29,32 Therefore, shifting the focus towards a more holistic strategy aimed at preventing maladaptive pain or at least reducing the risk of its occurrence appears to be more indicated.28,32,35 This concept follows the notion that i) events leading to acute pain, peripheral and central hyperalgesia, neuropathic pain, with or without allodynia occur simultaneously and are interrelated; ii) drugs may exhibit a specific activity against only certain components of the pain syndrome; iii) early integration of drugs with anti-hyperalgesic or anti-neuropathic pain activity into the treatment plan promises to reduce the risk of maladaptive pain development; and iv) loco-regional analgesia techniques help suppressing the occurrence of hyperalgesia and neuropathic pain.32 Accordingly, effective pain management in horses with laminitis favors a multi-modal approach that involves, from the beginning, a combination of drugs with different pharmacological mechanisms of action and different target sites within the somatosensory neural conduit (Figure 1). This concept may also include podiatric care, electrotherapy, tenotomy or botulinum toxin-induced relaxation of the deep digital flexor tendon, physical therapy, and other complementary modalities of treatment, most of them aimed at altering biomechanical forces on the affected digit with decreased foot pain perception and improved recovery.32,35,41,42,44,45,50-54

To have sustainable success pain therapy in the horse with chronic laminitis has to accomplish multiple goals: i) reduction of nociceptive signal generation in sensory nerve terminals (NSAIDs, podiatric care); ii) suppression of peripheral hyperalgesia (NSAIDs, local anesthesia and analgesia); iii) Inhibition/prevention of afferent nociceptive signal transmission to the central nervous system (loco-regional analgesia); iv) inhibition of spinal nociceptive signal transmission and central hyperalgesia development ([epidural/spinal: local anesthetics, opioids, \( \alpha_2 \) agonists], [systemic: opioids, \( \alpha_2 \) agonists, ketamine, NSAIDs, gabapentin, pregabalin]) and v) prevention and/or inhibition of neuropathic pain (systemic lidocaine, opioids, NSAIDS, gabapentin, pregabalin). Multi-modal pain therapy is mechanism driven and should be evidence based. It
represents a concept that is very open and allows new drugs and techniques to be included as they become available.

As mentioned before, neither pathological mechanisms leading to nor treatment of sensory hyperalgesia and neuropathic pain have yet been studied in detail in horses. At this stage, the equine veterinarian must rely primarily on experimental animal data and experiences in human medical practice when developing an analgesic regimen for the horse with chronic foot pain. There are a number of lessons to be learnt from experiences with neuropathic pain therapy in the human patient: i) symptoms described by patients are many, including those listed in Table 2, and therefore the diagnosis of neuropathic pain is often challenging and diagnostic criteria are still evolving; ii) rarely, if ever, can one single pathophysiological mechanism be claimed responsible for generating and maintaining the symptoms of neuropathic pain; iii) individual variation in the response to anti-neuropathic pain medications is substantial and unpredictable, thus favoring a stepwise process intended to identify the medication (or medication combination) that provides the greatest pain relief and fewest side effects while discontinuing drugs lacking an analgesic effect; iv) currently first line medications for neuropathic pain cannot be ranked by degree of efficacy; v) no more than 40-60 % of patients with neuropathic pain will respond favorably to pharmacological treatments.  

Whatever pharmacological or other approach and technique is chosen in an individual multi-modal protocol, the ultimate objective is to achieve optimum pain control during each phase of laminitis, while at the same time minimizing the risk of negatively affecting the disease process itself or causing side effects of drug therapy.
Conventional systemic analgesics

Three different pharmacological classes of drugs are commonly administered systemically to treat pain in horses affected with laminitis: NSAIDs, opioids and lidocaine. As described in more detail below, these drugs have also the potential to ameliorate nociceptive processes involved in the development of hyperalgesia and neuropathic pain.

NSAIDs

The backbone of any pharmacological pain therapy in laminitis has been and continues to be treatment with NSAIDs (Table 3). Evidence of increased cyclooxygenase (primarily COX-2) expression, leucocyte migration, and cytokine production in the developmental and acute phases of laminitis as outlined above indicated a role for these agents, optimally prior to the onset of lameness. However, there is increasing evidence to suggest that commonly administered NSAIDs such as phenylbutazone, flunixine meglumine, ketoprofen, and naproxen do not mediate their effects through antiinflammatory action (i.e. prostanoid synthesis inhibition) in the affected dermoepidermal hoof tissues but instead produce analgesia primarily by inhibition of central sensory neurons through COX-dependent and other independent mechanisms. First, administration of NSAIDs during the developmental stage, when COX-2 expression is upregulated, does not seem to prevent acute laminitis or alter the course of the disease arguing against a dominant antiinflammatory action. Second, increased prostaglandin activity has not been detected in the acute and chronic phases of laminitis despite evidence for ongoing inflammation, supporting the notion that if NSAIDS exhibit antiinflammatory activity at high doses this effect may not be related to inhibition of prostanoid synthesis. Third, unlike in peripheral tissues, where COX-1 is constitutively present for tissue homeostasis and COX-2 is inducible by inflammation, both COX isoforms are constitutively present in the CNS but with functionally different roles.

While NSAID administration in higher doses with antiinflammatory activity may be desirable in the very early (developmental) stage of laminitis, in the acute phase persistent and very effective pain relief from NSAIDs must be balanced against the risks of exacerbated structural damage due to excessive movement and limb loading of the horse, and thus the dose should be titrated based on the comfort level of the animal. In horses with chronic laminitis, effective analgesia frequently calls for high doses of NSAIDs and an effect may still not be seen for up to 3 days after initiation of treatment. This must be considered when assessing the clinical response to NSAIDs.
The previously held belief that more COX-2 preferential (meloxicam, Metacam®; etodolac, Etogesic®) or even COX-2 selective NSAIDs (firocoxib, Equioxx®; etodolac, Etogesic®; meloxicam, Metacam®; firocoxib, Equioxx®) are therapeutically superior has been challenged recently. New laboratory data indicate that suppression of inflammation-evoked central nociceptive activity and hyperalgesia by NSAIDs may be related to the selectivity for COX isoforms since COX-2 seems to be only involved in the initiation but not necessarily the maintenance of nociceptive spinal neuron activation, which may largely depend on COX-1. In contrast, in the absence of peripheral inflammation spinally initiated hyperalgesia has been shown to be mediated exclusively by constitutive COX-2 likely localized within the spinal cord dorsal horn, which argues for a prominent indication of selective COX-2 inhibitors as antihyperalgesic agents under circumstances of non-inflammation dependent central nociceptive sensitization.

Under the premise of inflammation being the common pathological denominator and hence the trigger for increased spinal sensory nerve excitability in all forms of laminitis, these laboratory findings suggest the use of non-selective NSAIDs as more effective candidates for analgesic therapy in laminitis. This idea is supported by two observations: i) among clinicians the non-selective COX inhibitor phenylbutazone is considered the most potent and most consistent pain relieving NSAID in laminitis; and ii) only ketoprofen (3.63 mg/kg), a slightly COX-1 preferential NSAID, may reduce foot pain to a greater extent than phenylbutazone (2.2 mg/kg).

Interestingly, the stereoisomers of ketoprofen are known to exert antinociceptive actions also through mechanisms other than COX inhibition. The R(-)-enantiomer of ketoprofen suppresses tactile allodynia via a yet to be defined mechanism of action and the S(+)-enantiomer produces analgesia through mechanisms involving serotonergic pathways both at the spinal and supraspinal level. In addition, ketoprofen has been demonstrated to exert antihyperalgesic activity in dairy cows suffering from unilateral hindlimb lameness.

A risk of toxicity must be anticipated in animals receiving protracted courses of NSAID treatment. Of interest, NSAIDs have been shown in-vitro to slightly potentiate MMP activation, which cautions against an indiscriminate use in the early stages of laminitis. Currently most widely used NSAIDs are non-selective and may cause multiple adverse effects (i.e. right dorsal colitis, gastric ulceration, and renal tubular necrosis) through inhibition of COX-1. This applies particularly to phenylbutazone which has a longer elimination half life and thus accumulates more extensively in tissues than other non-selective NSAIDs. Therefore, their use may need to be restricted in horses with compromised gastro-intestinal or renal functions or in dehydrated animals, and in ponies that are more susceptible to toxic effects of NSAIDs. In those cases
COX-2 preferential/selective agents and ketoprofen, that have a more favorable side effect profile compared to phenylbutazone and flunixin meglumine, may be better choices to treat persistent pain in laminitis.\textsuperscript{75,76}

**OPIOIDS**

Opioids (Table 4) are generally indicated in moderate to severe pain, however, their analgesic efficacy in horses compared to other species is less well defined, especially when used in clinically common doses.\textsuperscript{60,77,78} At higher doses known to produce significant analgesia or antinociception (e.g., butorphanol, methadone, or morphine ≥ 0.1 mg/kg) opioids commonly provoke central excitatory responses, requiring combination with sedatives such as acepromazine or $\alpha_2$ agonists (Table 4).\textsuperscript{60,77,78} In addition, they decrease gastrointestinal motility and cause colon impaction, thus limiting their long-term use in animals with chronic laminitis. Combining lower doses of $\mu$-opioids with low doses of $\alpha_2$ agonists (preferably in the form of a constant rate infusion [CRI]) may help achieve a desired level of analgesia by making use of the well known analgesic synergism between the two drug classes, while avoiding the profound CNS stimulatory effects of the opioids and hemodynamic effects of the $\alpha_2$ agonists (Table 4).\textsuperscript{78} However, impaired intestinal motility, caused by both opioids and $\alpha_2$ agonists, remains a concern with long-term treatment. Whether opioids elicit less CNS stimulatory effects and are therapeutically more effective in horses experiencing severe pain is controversial because scientific evidence is lacking.\textsuperscript{79} Controlled trials in human patients revealed efficacy of opioids against peripheral neuropathic pain and some components of central neuropathic pain.\textsuperscript{56,57} However, there is also laboratory animal and human clinical evidence that long-term use of $\mu$ opioid agonists such as morphine can trigger the development of a state of opioid induced hyperalgesia (OIH) whereby a subject receiving opioids for the treatment of pain may actually become more sensitive to pain.\textsuperscript{80-82} This potentially profound adverse effect should be considered when prescribing long-term opioid therapy in horses with chronic laminitis, even if the mechanisms leading to OIH and its clinical relevance are still being debated, and the phenomenon is not described in horses.\textsuperscript{83}

Butorphanol (Torbugesic\textsuperscript{®}), a $\kappa$ opioid receptor agonist and $\mu$-receptor antagonist, is probably the most widely used opioid in horses. The drug’s short half-life limits its use as analgesic in laminitis, calling for a CRI to achieve persistent analgesia.\textsuperscript{84,85} Transdermal administration of fentanyl (Duragesic\textsuperscript{®}), a potent but very short-acting synthetic $\mu$-opioid receptor agonist, has been found to not consistently alleviate musculoskeletal pain.\textsuperscript{86,87} If fentanyl patches were to be used as part of the multimodal pain management one should probably apply at least as many patches as necessary to achieve plasma fentanyl levels
generally considered to be analgesic in other species (i.e. $\geq 1$ ng/mL). Buprenorphine (Buprenex®) is a $\mu$-opioid agonist and $\kappa$-opioid antagonist, which has been claimed to have a ceiling effect. When applied as a sole analgesic agent in horses, measurable antinociception has been reported to occur at doses of 10 $\mu$g/kg or higher but significant excitement and hemodynamic stimulation were noted as well. Walker reported recently about experience with a 5-day administration of buprenorphine in a filly with severe head and neck trauma choosing the sublingual/buccal mucosal route. The drug provided clinically effective analgesia, when given twice daily, without provoking signs of excitement.

SYSTEMIC LIDOCAINE

The clinical use of systemic lidocaine for pain treatment in humans was first reported almost five decades ago, and during the past 10 years has gained much popularity also in equine practice. The drug must be administered as CRI due to its short half-life. A loading dose of 1.3 to 1.5 mg/kg administered IV over 15 minutes (min) followed by a CRI of 50-100 $\mu$g•kg$^{-1}$•min$^{-1}$ is most commonly used. Data regarding the immediate analgesic effect of lidocaine on spontaneous (not evoked) pain in animals or patients are somewhat inconsistent when infused at clinically common doses, and higher doses carry the risk of cardio- and neurotoxicity. Since plasma concentrations achieved during long-term infusion vary widely among horses and may accumulate over time, monitoring of plasma levels (via a lidocaine ELISA kit; Neogen Corporation, Lansing, MI 48912, USA) is recommended, not only to avoid toxicity but also to ensure that analgesically effective concentrations (approx. $\geq 1$ $\mu$g/mL) are being achieved.

Information available to date indicates that the analgesic action of IV lidocaine is far more complex than previously thought. Besides its well studied local anesthetic actions (i.e. Na$^+$ channel blockade) in the peripheral and central nervous system, it also exerts multiple other mechanisms of action that target the nociceptive system (spinal and supraspinal). Both laboratory animal and controlled clinical trials in humans have found IV lidocaine to suppress development of peripheral hyperalgesia as well as central nociceptive sensitization and allodynia. Its efficacy as an analgesic and anti-neuropathic agent has recently been demonstrated in adult patients suffering from chronic pain with tactile hyperalgesia and/or mechanical allodynia for more than 3 months as a result of a peripheral nerve injury. In this trial IV lidocaine failed to produce an alleviation of the spontaneous pain the patients were suffering from the nerve injury, similar to findings in a previous
study from the same investigator group.\textsuperscript{97} However it is also reported elsewhere that systemic lidocaine inhibits spontaneous pain.\textsuperscript{91,107}

In addition to its analgesic and antihyperalgesic/anti-neuropathic properties described above lidocaine also has inflammation modifying effects and has been shown to protect tissues against ischemic and reperfusion injuries in various species including the horse,\textsuperscript{108-112} which may all have a direct or indirect impact on the laminitis disease process and thus related nociceptive mechanisms and pain perception.
Non-conventional systemic analgesics with anti-hyperalgesic and anti-neuropathic pain activity

Three evidence-based consensus guidelines for the pharmacologic treatment of neuropathic pain have been published recently in the human medical literature. These guidelines all recommend tricyclic antidepressants (not tested in the equine species) and calcium channel \( \alpha_2\delta \) ligands (gabapentin, pregabalin) as first-line treatments for patients with neuropathic pain. They suggest reserving opioid analgesics and N-methyl-D-aspartate (NMDA) receptor antagonists as second- or third-line options in most cases, despite evidence of efficacy in certain forms of hyperalgesia and neuropathic pain. In two of the guidelines topical lidocaine was recommended as a first-line treatment for patients with localized peripheral neuropathic pain.

CALCIUM CHANNEL \( \alpha_2\delta \)-LIGANDS (GABAPENTIN, PREGABALIN)

The anticonvulsant drugs gabapentin and pregabalin both bind with high affinity to the \( \alpha_2\delta \)-1 subunit of voltage-gated calcium channels in the spinal cord and brain. As a result neuronal calcium currents are inhibited, ultimately causing a change in the release of neurotransmitters within the CNS such as glutamate, GABA, norepinephrine, and SP; these actions account for much of the analgesic activity of these compounds. The expression of the \( \alpha_2\delta \)-1 subunit has been shown to increase in chronic pain states, as well as in both afferent sensory neurons and in the spinal cord dorsal horn in experimental neuropathic pain models. This correlates well with the observation that gabapentin exerts analgesic properties primarily in sensitized or hyperalgesic states. More recently gabapentin and pregabalin have been used clinically in humans to treat a variety of neuropathic pain states and early post-surgical pain, often but not always with success. These drugs appear especially effective in patients with paroxysmal pain (lancinating/shooting pain), brush-induced allodynia and cold-induced allodynia/hyperalgesia, in whom it significantly lowers pain scores. Laboratory animal data suggest the \( \alpha_2\delta \)-ligands also have activity against opioid-induced hyperalgesia.

Documented therapeutic use in horses refers only to oral (PO) administration of gabapentin (Neurontin®) in two animals which were thought to exhibit signs of neuropathic pain, one in conjunction with acute femoral nerve injury post-surgery and one with a history of white line disease and chronic laminitis. Lacking information on pharmacokinetic properties of the drug in the equine at that time, gabapentin doses were extrapolated from use in other species (2.5 mg/kg
at intervals of 8, 12 or 24 hrs;\textsuperscript{124} 2.0-3.3 mg/kg at intervals of 8 or 12 hrs\textsuperscript{35}). In the meantime two studies have been conducted in horses investigating the drug’s pharmacokinetic properties as well as behavioral and cardiovascular parameters after IV and PO administration.\textsuperscript{126,127} After IV (over 30 min) and PO administration of gabapentin (20 mg/kg), the median elimination half-lives were 8.5 and 7.7 hrs, respectively which correspond well with data in other species.\textsuperscript{126} After IV administration plasma gabapentin concentrations remained above the 3-4 µg/mL range for approximately 15 hrs, similar to the dose associated with significant analgesic effects in adult human volunteers.\textsuperscript{128} In the horse, oral bioavailability of gabapentin is relatively poor (~ 16 %) and therefore plasma gabapentin concentrations decreased much more rapidly than after IV drug administration (i.e. within 2-3 hrs) below the analgesic threshold. Neither route of gabapentin administration was associated with effects on heart rate, rhythm or blood pressure, nor pronounced central nervous effects, which concurs in other species.\textsuperscript{127} Further research is required to establish a dosage that will provide effective analgesia in horses with chronic laminitis and to determine if combinations with other agents create an enhanced effect.

**KETAMINE**

Peripheral sensory nerve stimulation leads to activation of the ligand-gated ion channel complex known as N-methyl-D-aspartate (NMDA) receptors on the postsynaptic membrane in the dorsal horn of the spinal cord. Release of NMDA, a modulating neurotransmitter, is coupled with subsequent release of the excitatory neurotransmitter glutamate.\textsuperscript{22} The resultant extended depolarization of sensory neurons produces much larger than usual postsynaptic potentials, known as synaptic potentiation, a key component of central hyperalgesia as well as synaptic plasticity leading to chronic pain.\textsuperscript{22,129,130} Ketamine is an NMDA receptor antagonist.\textsuperscript{131,132} At subanesthetic doses (100-150 µg/kg as initial bolus followed by a CRI of 60-120 µg•kg\textsuperscript{-1}•hr\textsuperscript{-1}) it blocks NMDA receptors, thereby modulating central sensitization induced both by tissue damage.\textsuperscript{133-137} Ketamine exhibits synergism with classical analgesics such as opioids, NSAIDs, local anesthetics and \(\alpha_2\) agonists; therefore it reduces opioid analgesic consumption and increases analgesic quality.\textsuperscript{135-137} Ketamine is used primarily as an antihyperalgesic and anti-allodynic compound in human patients at risk of developing maladaptive pain after major tissue damage and not primarily as an analgesic agent per se.\textsuperscript{138}
Clinical effects of subanesthetic ketamine infusion (400 and 800 $\mu$g•kg$^{-1}$•hr$^{-1}$) have been studied in awake horses.$^{139}$ During or following the 12 hr infusion no analgesic effects could be demonstrated and no signs of excitement or significant changes in measured physiological variables occurred. A CRI of 400-1500 $\mu$g•kg$^{-1}$•hr$^{-1}$ has been used safely in conscious horses.$^{140}$ However, with both infusion regimens the measured plasma ketamine concentrations were about 10 times below concentrations (2-4 $\mu$g/mL) associated with measurable acute antinociceptive effects.$^{141}$ Matthews et al.$^{142}$ administered ketamine via infusion (400 and 800 $\mu$g•kg$^{-1}$•hr$^{-1}$) for up to 5 days in eight horses with osteomyelitis, septic joint disease, burns, or colic in a search for possible analgesic effects. Responses to ketamine varied substantially with some showing any or only slight improvements of pain symptoms, while others appeared to be markedly more comfortable within 6 to 12 hrs of the start of drug infusion. Thus, in horses as in humans, low dose ketamine infusion should be considered an adjunctive therapy for treating central hyperalgesia.

**Loco-regional anesthesia and analgesia**

The neuropathophysiological processes leading to the development of central hyperalgesia, neuropathic pain and allodynia are primarily triggered by increased spontaneous firing activity in ascending sensory nerve fibers during the first 4-5 days following peripheral nerve injuries.$^{143-145}$ Experimental evidence and clinical experiences in human medicine indicate that central hyperalgesia can be obliterated by no other treatment modality as effectively as by loco-regional anesthesia and analgesia aimed at interrupting or diminishing impulse trafficking from the site of tissue injury to the CNS and within the dorsal horn of the spinal cord.$^{56,59,78,143-147}$ Those techniques may include wound infiltration or joint injections with local anesthetics, topical local anesthetic application using lidocaine patches, repetitive or even better continuous peripheral nerve blocks, and epidural or intrathecal anesthesia and analgesia.

Continuous peripheral nerve blockade (CPNB) is a treatment modality that has been long introduced in human medicine and is currently widely applied in orthopedic and trauma surgery. The technique entails continuous or intermittent low-dose administration of local anesthetics via catheters placed along peripheral nerves, thus providing persistent pain control while reducing the need of systemic medications.$^{148}$ A technique for percutaneous placement of catheters along the palmar nerves in the standing, sedated horse was recently developed and provides a method for repeated or continuous perineural administration of low concentrated local anesthetic solutions (e.g. bupivacaine or ropivacaine 0.125-0.25 %) over a period of multiple days.$^{148,149}$ The therapy can
continue for longer periods by exchange catheters every 4-8 days. With this technique significant pain relief can be obtained in horses refractory to systemic analgesic therapy and therefore suffering from unrelenting pain during a period of early or active chronic laminitis.\textsuperscript{149} The technique offers the advantage of titrating the analgesic effect by adjusting the concentration of the local anesthetic solution and/or the rate of drug administration to a desired level of comfort without causing complete sensory blockade. The CPNB catheters can also be placed more proximal on the limb in close proximity of the ulnar and median nerves.\textsuperscript{150} This technique may serve as an alternative for providing significant reduction of pain perception in the distal forelimb.\textsuperscript{150} However, the use of either CPNB technique in the acute phase of laminitis is controversial and warrants further clinical study. A pronounced nociceptive blockade of the affected limb will allow the horse to increase the load on the foot and potentially exacerbate the disruption of the lamellar dermal-epidermal bond.

In horses experiencing severe pain due to chronic laminitis in their hindlimb(s) caudal epidural administration of analgesics such as opioids (e.g. morphine 0.1-0.2 mg/kg), \(\alpha_2\) agonists (e.g. xylazine 0.17 mg/kg; detomidine 20-30 \(\mu\)g/kg) or a combination thereof with or without low (i.e. motor function not compromising) doses of local anesthetic (e.g. bupivacaine or ropivacaine 0.125-0.25 \%) provides long-term pain control.\textsuperscript{151} To allow repeated drug administration it is recommended to place an epidural catheter.\textsuperscript{151} Medications may be administered in form of intermittent boluses (15-30 mL) or as an infusion (0.5-3.0 mL/hr). As with the CPNB techniques similar restrictions apply to the use of epidural analgesia in the acute phase of laminitis.

**SUMMARY**

Managing pain in horses with chronic laminitis is often challenging as the disease process triggers a cascade of events that turns the somatosensory nervous system into a state of nociceptive hyperactivity with abnormal impulse processing often unresponsive to classic anti-inflammatory drug treatment. Appreciating this maladaptive pain state as the product of complex neuropathological processes affecting both the peripheral and central somatosensory nervous system is crucial when devising a treatment plan for horses afflicted by chronic laminitis. Effective analgesia calls from the outset for a multi-modal approach that involves a combination of agents with different pharmacological mechanisms of action targeting different sites within the nociceptive system and requires both systemic and local/regional drug administration. A pain grading system should be applied that allows for objective pain assessment and close monitoring of changes in nociception as a result of disease progress and/or response to analgesic therapy.
REFERENCES


114. Taylor CP. The biology and pharmacology of calcium channel \( \alpha_2\delta \) proteins. CNS Drug Rev 2004;10(2):183-8.


Table 1: Modified composite pain score (MCPS). \(^{35}\)

<table>
<thead>
<tr>
<th>Grade</th>
<th>Descriptor</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Frequent shifting of weight between the feet with no discernible lameness at the walk.</td>
</tr>
<tr>
<td>2</td>
<td>Does not resist having a foreleg lifted, is not reluctant to walk, but does show lameness at the walk.</td>
</tr>
<tr>
<td>3</td>
<td>Resists having a foreleg lifted and is reluctant to walk.</td>
</tr>
<tr>
<td>4</td>
<td>Walks only if forced.</td>
</tr>
</tbody>
</table>

**Dynamic score: Modified Obel Grading System**

<table>
<thead>
<tr>
<th>Score</th>
<th>Descriptor</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>No pain or distress: normal behaviour.</td>
</tr>
<tr>
<td>2</td>
<td>Mild pain: irritable, restless, decreased appetite.</td>
</tr>
<tr>
<td>3</td>
<td>Mild pain: 2 plus resists handling.</td>
</tr>
<tr>
<td>4</td>
<td>Mild-moderate pain: 3 plus standing in back of stall or with back to stall door.</td>
</tr>
<tr>
<td>5</td>
<td>Moderate pain: 4 plus camped-out legs, increased digital pulses.</td>
</tr>
<tr>
<td>6</td>
<td>Moderate-severe pain: 5 plus frequent recumbency, HR &gt; 44 beats/min, and/or RR &gt; 24 breaths/min.</td>
</tr>
<tr>
<td>7</td>
<td>Moderate-severe pain: 6 plus sweating, muscle fasciculation, head-tossing.</td>
</tr>
<tr>
<td>8</td>
<td>Severe pain: 7 plus unwilling to move.</td>
</tr>
<tr>
<td>9</td>
<td>Severe-extreme pain: 8 plus not weight bearing when standing.</td>
</tr>
<tr>
<td>10</td>
<td>Extreme pain: 9 or entirely recumbent, bordering on agonal.</td>
</tr>
</tbody>
</table>

**Static score: Modified from Glasgow composite scale**

**Maximum possible score: 14**
Table 2: Sensory symptoms and signs associated with neuropathic pain.55

<table>
<thead>
<tr>
<th>Symptom or Sign</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Allodynia</td>
<td>Pain due to non-noxious stimuli (e.g. light touch) when applied to the affected area. May be mechanical (e.g., caused by light pressure), dynamic (caused by non-painful movement of a stimulus), or thermal (caused by non-painful warm, or cool stimulus).</td>
</tr>
<tr>
<td>Anesthesia</td>
<td>Loss of normal sensation to the affected region.</td>
</tr>
<tr>
<td>Hyperalgesia</td>
<td>Exaggerated response to a mildly noxious stimulus applied to the affected region.</td>
</tr>
<tr>
<td>Hyperpathia</td>
<td>Delayed and explosive response to a noxious stimulus applied to the affected region.</td>
</tr>
<tr>
<td>Referred pain</td>
<td>Occurs in a region remote from the source of stimulation.</td>
</tr>
</tbody>
</table>
Table 3: Doses of commonly used non-steroidal antiinflammatory drugs (NSAIDs) in horses.

<table>
<thead>
<tr>
<th>Non-Steroidal Anti-Inflammatory Drug</th>
<th>Dose, route &amp; interval of drug administration*</th>
<th>Comments</th>
<th>References</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Non-selective COX-1 &amp; 2 inhibitors</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Phenylbutazone</td>
<td>2.2-4.4 (up to 6) mg/kg IV/PO SID-BID</td>
<td>Highest toxicity among NSAIDs</td>
<td>43,44,47,55, 62,64,68,73</td>
</tr>
<tr>
<td>Flunixine meglumine</td>
<td>1.1 mg/kg IV/PO SID-BID</td>
<td>Cases of muscle necrosis reported with IM injection</td>
<td>47,68,73</td>
</tr>
<tr>
<td>Ketoprofen</td>
<td>2.2-3.6 mg/kg IV/IM SID-QID</td>
<td>Only parenteral administration</td>
<td>55,64,68,73</td>
</tr>
<tr>
<td>Vedaprofen</td>
<td>1-2 mg/kg IV/PO SID-BID</td>
<td>Limited experience</td>
<td>73,74</td>
</tr>
<tr>
<td>Eltenac</td>
<td>0.5-1 mg/kg IV SID</td>
<td>Limited experience</td>
<td>68, 73,74</td>
</tr>
<tr>
<td>Naproxen</td>
<td>5 mg/kg IV</td>
<td>Initially slow IV bolus, then PO</td>
<td>73</td>
</tr>
<tr>
<td></td>
<td>10 mg/kg PO SID</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Preferential or selective COX-2 inhibitors</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Meloxicam</td>
<td>0.6 mg/kg IV/PO SID-BID</td>
<td></td>
<td>68, 73,74</td>
</tr>
<tr>
<td>Etodolac</td>
<td>10-20 mg/kg IV/PO SID-BID</td>
<td>Limited experience</td>
<td>68,73</td>
</tr>
<tr>
<td>Firocoxib</td>
<td>0.1 mg/kg PO SID</td>
<td>May require 0.3 mg/kg on 1st day of administration</td>
<td>69,70,73</td>
</tr>
</tbody>
</table>

Routes and intervals of drug administration: IV, intravenous; IM, intramuscular; PO, per os; SID, once daily; BID, twice daily; TID, three times daily. *Caution: More rapid metabolism and elimination of most NSAIDs in mules and donkeys may require more frequent dosing.*

62
Table 4: Doses of opioids and co-administered sedatives in horses.

<table>
<thead>
<tr>
<th>Drug</th>
<th>Dose, route &amp; interval of drug administration</th>
<th>References</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Opioids</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Morphine</td>
<td>0.1-0.2 mg/kg IV/IM every 4-6 hrs</td>
<td>73,74</td>
</tr>
<tr>
<td>Methadone</td>
<td>0.1-0.2 mg/kg IV/IM every 4-6 hrs</td>
<td>73,74</td>
</tr>
<tr>
<td>Butorphanol</td>
<td>0.01-0.4 mg/kg IV, IM every 2-4 hrs&lt;sup&gt;1&lt;/sup&gt;</td>
<td>55,72,73,74,</td>
</tr>
<tr>
<td></td>
<td>Bolus of 18 µg/kg bolus followed by IV CRI at 13-24 µg•kg&lt;sup&gt;-1&lt;/sup&gt;•hr&lt;sup&gt;-1&lt;/sup&gt;</td>
<td>79,80</td>
</tr>
<tr>
<td>Buprenorphine</td>
<td>5-20 µg/kg IV/IM TID</td>
<td>73,84,85</td>
</tr>
<tr>
<td></td>
<td>6 µg/kg sublingual BID</td>
<td></td>
</tr>
<tr>
<td>Fentanyl</td>
<td>2-3 10 mg (100 µg/hr) patches to be changed every 3 days</td>
<td>81,82,83</td>
</tr>
<tr>
<td><strong>Co-administered phenothiazine and/or α&lt;sub&gt;2&lt;/sub&gt; agonist sedative/analgesic</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Acepromazine</td>
<td>0.01-0.08 mg/kg IV/IM/SC BID/TiD or CRI at 2-4 µg•kg&lt;sup&gt;-1&lt;/sup&gt;•hr&lt;sup&gt;-1&lt;/sup&gt;</td>
<td>41,47,48</td>
</tr>
<tr>
<td>Detomidine</td>
<td>10-40 µg/kg IM/IV every 2-4 hrs</td>
<td>32,73,74</td>
</tr>
<tr>
<td></td>
<td>Bolus&lt;sup&gt;2&lt;/sup&gt; of 5-10 µg/kg IV followed by CRI at 24-36 µg•kg&lt;sup&gt;-1&lt;/sup&gt;•hr&lt;sup&gt;-1&lt;/sup&gt;</td>
<td></td>
</tr>
<tr>
<td>Medetomidine</td>
<td>5-7 µg/kg IM/IV every 2-4 hrs</td>
<td>32,73,74</td>
</tr>
<tr>
<td></td>
<td>Bolus&lt;sup&gt;2&lt;/sup&gt; of 3-7 µg/kg IV followed by CRI at 1.5-3.6 µg•kg&lt;sup&gt;-1&lt;/sup&gt;•hr&lt;sup&gt;-1&lt;/sup&gt;</td>
<td></td>
</tr>
<tr>
<td>Dexmedetomidine</td>
<td>Bolus&lt;sup&gt;2&lt;/sup&gt; of 1.5-3.0 µg/kg IV followed by CRI at 0.75-1.8 µg•kg&lt;sup&gt;-1&lt;/sup&gt;•hr&lt;sup&gt;-1&lt;/sup&gt;</td>
<td></td>
</tr>
</tbody>
</table>

Routes and intervals of drug administration: IV, intravenous; IM, intramuscular; SC, subcutaneously; SID, once daily; BID, twice daily; TID, three times daily; CRI, constant rate infusion. <sup>1</sup>Significant central excitatory
responses to be expected from doses of > 0.05 mg/kg onwards. A bolus administration is optional but not always necessary, dependent on opioid dose and route of administration. Acepromazine has also been employed to improve perfusion of the hoof\textsuperscript{41,46,483} even though recent studies have questioned the magnitude of such an effect.\textsuperscript{152}
Figure 1: Multimodal approach to pain management in the horse with chronic laminitis (see text for more detail).